ClinicalTrials.gg
CompletedNCT05747430RELIEFUpdated Apr 3, 2026

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

A Phase 2 interventional study of IRX-101 and Providone-Iodine in Retinal Disease, sponsored by iRenix Medical, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by iRenix Medical, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.

Enrollment
26th of 111
155 · median 36
Started
2023
with 9 others
Phase 2
25 of 162
2 open now
Registered
138th of 162
by date

Among the 162 studies in Retinal Diseases with a site in United States, this one is the 26th largest by enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2023, is one of 25 in phase 2, and was the 138th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Retinal Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 15 centers in the United States (US).

03

Conditions studied

  • Retinal Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes

Exclusion criteria

Exclusion Criteria:

  1. Current or past diagnosis of endophthalmitis
  2. Current diagnosis of uveitis
  3. Monocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eye
  4. Current use of viscous lidocaine products for ocular anesthesia prior to IVT
  5. Currently receiving intravitreal injections
  6. Concurrent participation in another clinical trial
  7. Females who are pregnant, planning to become pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    IRX-101

    Subjects randomized to IRX-101 will receive the investigational product, IRX-101.

    Drug: IRX-101

  • Active comparator
    5% Povidone-iodine

    Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.

    Drug: Providone-Iodine

Interventions

  • IRX-101 is a novel ocular anti-septic

  • DrugProvidone-Iodine

    5% Providone-Iodine

06

What researchers measure

Primary outcomes

  1. Safety of new drug

    Safety will be measured via slit lamp and fundoscopic examinations

    Time frame: 1-hour and 1-week post-treatment

Secondary outcomes

  1. Mean corneal fluorescein staining scores

    Compare mean corneal fluorescein staining scores obtained after IVT in the IRX-101 and standard of care groups; corneal staining will be obtained using the validated Oxford Corneal Staining scale of 0 (no staining) to 5 (maximal staining)

    Time frame: Immediately following intraviteral injection

  2. Patient-reported post-injection pain scores

    Compare mean patient-reported post-injection pain scores 1-hour post-administration; pain will be assessed using the visual analog pain scale, a validated patient-reported outcome measure (questionnaire) for assessing patient's subjective pain and discomfort

    Time frame: 1-hour post-administration

07

Study locations

7 sites
  • Coastal Eye Surgeons, LLC
    Greenwich, Connecticut 06830, United States
  • Mississippi Retina Associates
    Madison, Mississippi 39110, United States
  • Erie Retina Research, LLC
    Erie, Pennsylvania 16507, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Retina Consultants of Texas
    Katy, Texas 77494, United States
  • Edward Wood, MD
    Round Rock, Texas 78681, United States
  • Retina Associates of Utah
    Salt Lake City, Utah 84107, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Mar 2025, 24 months.

Of 18 phase 2 interventional studies under Retinal Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 38. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Feb 28, 2023
StartActual
Feb 22, 2023
Primary completionActual
Mar 6, 2025
CompletionActual
Mar 31, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05747430
Lead sponsor
iRenix Medical, Inc.
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
Feb 22, 2023
Primary completion
Mar 6, 2025
Completion
Mar 31, 2026
Last update
Apr 3, 2026

Study contacts

Stephen Smith, MD
study chair · Founder

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IRX-101

Start the discussion